Antisense Therapeutics Ltd ATHJF:OTCPK

RT Quote | Exchange | USD
Last | 05/18/22 EDT
0.07UNCH (UNCH)
52 week range
0.07 - 0.30
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.07
  • 52 Week High0.30
  • 52 Week High Date10/29/21
  • 52 Week Low0.07
  • 52 Week Low Date05/18/22

Key Stats

  • Market Cap39.69M
  • Shares Out573.99M
  • 10 Day Average Volume10,000
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-53.33

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.07
  • 52 Week High0.30
  • 52 Week High Date10/29/21
  • 52 Week Low0.07
  • 52 Week Low Date05/18/22
  • Market Cap39.69M
  • Shares Out573.99M
  • 10 Day Average Volume10,000
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-53.33

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-6.22
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Antisense Therapeutics Ltd

There is no recent news for this security.

Profile

MORE
Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company's product...
Robert Moses
Independent Non-Executive Chairman of the Board
Phillip Hains
Chief Financial Officer, Joint Company Secretary
Address
6 Wallace Ave, Toorak
Melbourne, VIC
3142
Australia